每年專案
個人檔案
學歷
- 2006 臺灣大學藥學博士
- 1993 臺灣大學醫學院藥研所碩士
- 1991 臺北醫學大學藥學系學士
經歷
- 2012- 臺北醫學大學藥物科學學科副教授
- 2016-2019 臺北醫學大學藥物科學學科主任
- 2012-2012 臺北醫學大學藥物科學學科助理教授
- 2007-2012 臺北醫學大學藥學系助理教授
- 2007-2012 臺北醫學大學醫學科學研究所助理教授
- 2004-2007 臺北醫學大學生化學科助理教授
- 1998-2004 臺北醫學大學生化學科講師
- 1995-1998 臺北醫學大學生化學科助教
研究興趣
- 生物有機合成
- 藥物修飾設計等研究開發
- 天然物成分及生化性質研究
指紋
- 1 類似的個人檔案
網路
-
「112年度「藥品品質規範國際協和化」委託辦理計畫」之「分項計畫二:原料藥及賦形劑品質規範國際協和化」
1/16/23 → 12/31/23
研究計畫: A - 政府部門 › c - 衛生福利部暨其附屬機構
-
-
-
-
-
Design, Structure–Activity Relationships, and Enzyme Kinetic Studies of Tricyclic and Tetracyclic Coumarin–based Sulfamates as Steroid Sulfatase Inhibitors
Chiu, P-F., Lin, I-C., Lu, Y-L., Chang, C-N., Chan, H-Y., Lin, T-S., Tsai, K-C., S. Y. Hsieh, Y., Chen, M-J., Lin, M-H. & Liang, P-H., 2023, (接受/付印) 於: Bioorganic Chemistry.研究成果: 雜誌貢獻 › 文章 › 同行評審
-
Preclinical Therapeutic Assessment of a New Chemotherapeutics [Dichloro(4,4’-Bis(2,2,3,3-Tetrafluoropropoxy) Methyl)-2,2’-Bipryridine) Platinum] in an Orthotopic Patient-Derived Xenograft Model of Triple-Negative Breast Cancers
Kan, T. C., Lin, M. H., Cheng, C. C., Lu, J. W., Sheu, M. T., Ho, Y. S., Rahayu, S. & Chang, J., 4月 2022, 於: Pharmaceutics. 14, 4, 839.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取1 引文 斯高帕斯(Scopus) -
The Design, Structure–Activity, and kinetic studies of 3-Benzyl-5-oxa-1,2,3,4-Tetrahydro-2H-chromeno-(3,4-c)pyridin-8-yl sulfamates as Steroid sulfatase inhibitors
Chang, C-N., Lin, I-C., Lin, T-S., Chiu, P-F., Lu, Y-L., Narwane, M., Liu, I-C., Hng, Y., Tsai, K-C., Lin, M-H., S. Y. Hsieh, Y., Chen, M-J. & Liang, P-H., 2022, 於: Bioorganic Chemistry. 129研究成果: 雜誌貢獻 › 文章 › 同行評審
1 引文 斯高帕斯(Scopus) -
Corrigendum to “Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response” [Eur J Med Chem. 192 2020 112158] (European Journal of Medicinal Chemistry (2020) 192, (S0223523420301252), (10.1016/j.ejmech.2020.112158))
Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., 6月 15 2020, 於: European Journal of Medicinal Chemistry. 196, 112329.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
Corrigendum to“Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo”[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086] (European Journal of Medicinal Chemistry (2020) 190, (S0223523420300532), (10.1016/j.ejmech.2020.112086))
Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., 9月 1 2020, 於: European Journal of Medicinal Chemistry. 201, 112404.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
資料集
-
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H. (Contributor), Lin, Y. (Contributor), Chao, M. (Contributor), Sung, T. (Creator), Wu, Y. (Creator), Chen, Y. (Creator), Lin, M. (Contributor), Liou, J. (Creator), Pan, S. (Contributor) & Yang, C. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4350887.v1, https://springernature.figshare.com/collections/The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/4350887/1
資料集: Dataset
-
Additional file 1: of The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H. (Contributor), Lin, Y. (Contributor), Chao, M. (Contributor), Sung, T. (Contributor), Wu, Y. (Contributor), Chen, Y. (Contributor), Lin, M. (Contributor), Liou, J. (Contributor), Pan, S. (Contributor) & Yang, C. (Contributor), Unknown Publisher, 12月 29 2018
DOI: 10.6084/m9.figshare.7531874.v1, https://springernature.figshare.com/articles/Additional_file_1_of_The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/7531874/1
資料集: Dataset